Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators. Ansquer JC, et al. Among authors: hanefeld m. Am J Cardiovasc Drugs. 2009;9(2):91-101. doi: 10.1007/BF03256580. Am J Cardiovasc Drugs. 2009. PMID: 19331437 Clinical Trial.
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Hanefeld M, et al. Cardiovasc Diabetol. 2011 Jul 14;10:65. doi: 10.1186/1475-2840-10-65. Cardiovasc Diabetol. 2011. PMID: 21756323 Free PMC article. Clinical Trial.
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators. Mohler ER 3rd, et al. Among authors: hanefeld m. J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079. J Am Coll Cardiol. 2008. PMID: 18436114 Free article. Clinical Trial.
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M. Ruilope L, et al. Among authors: hanefeld m. BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180. BMC Nephrol. 2014. PMID: 25407798 Free PMC article. Clinical Trial.
[Multimodal therapy of dyslipidemia].
Stahn A, Hanefeld M. Stahn A, et al. Among authors: hanefeld m. Clin Res Cardiol Suppl. 2011 May;6:10-6. doi: 10.1007/s11789-011-0031-5. Clin Res Cardiol Suppl. 2011. PMID: 22528173 Review. German.
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group. Russell-Jones D, et al. Among authors: hanefeld m. Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210563 Free PMC article. Clinical Trial.
399 results